For each study, data for the NAFLD and control groups were separately presented, including the number of patients (and men), age, BMI (kg/m2), waist circumference (cm), the number of patients with T2DM, FGF-21 levels (ng/ml), AST (IU/L), ALT (IU/L), GGT (IU/L), HOMA-IR, and the number of patients with NASH-related cirrhosis. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.